Inactive Instrument

Tyme Technologies, Inc.

Equities

TYME

US90238J1034

Biotechnology & Medical Research

Tyme Technologies, Inc, Appoints Michele Korfin as Chief Commercial Officer

October 15, 2018 at 08:00 am EDT

Tyme Technologies Inc, announced the appointment of former Kite Pharma and Celgene executive, Michele Korfin as the company’s Chief Commercial Officer. Most recently at Kite Pharma, Ms. Korfin oversaw the market access strategy, including payer relations and reimbursement, for YescartaÂ®, the first approved CAR-T therapy in lymphoma.

Latest news about Tyme Technologies, Inc.

Tyme Technologies, Inc.(NasdaqCM:TYME) dropped from S&P TMI Index	22-09-21	CI
Sector Update: Health Care Stocks Largely Resist Late Buying Support	22-09-19	MT
Sector Update: Health Care Stocks Retreating to Begin New Week	22-09-19	MT
Tyme Technologies, Inc.(NasdaqCM:TYME) dropped from NASDAQ Composite Index	22-09-19	CI
Tyme Technologies, Inc.(NasdaqCM:TYME) dropped from S&P Global BMI Index	22-09-19	CI
Syros Pharmaceuticals Closes Tyme Technologies Merger, Private Placement	22-09-16	MT
Tyme Technologies, Inc. Announces Board Changes	22-09-16	CI
Syros Pharmaceuticals, Inc. completed the acquisition of Tyme Technologies, Inc. from a group of shareholders.	22-09-15	CI
Syros Pharmaceuticals, Tyme Technologies Shares Surging in Late Trade After Shareholder Merger Nod	22-09-15	MT
Top Premarket Gainers	22-09-13	MT
Tyme Technologies, Inc. Reports Earnings Results for the First Quarter Ended June 30, 2022	22-08-09	CI
Sector Update: Health Care Stocks Decline Premarket Tuesday	22-07-05	MT
Sector Update: Health Care	22-07-05	MT
Top Premarket Gainers	22-07-05	MT
Syros Pharmaceuticals to Acquire Tyme Technologies in All-Stock Deal	22-07-05	MT
Earnings Flash (TYME) TYME TECHNOLOGIES Posts 2022 Loss of $-0.14	22-05-25	MT
Tyme Technologies Provides Update on Its Ongoing Strategic Options Process	22-05-25	CI
Tyme Technologies, Inc. Reports Earnings Results for the Full Year Ended March 31, 2022	22-05-25	CI
Tyme Technologies, Inc. Announces Exploration of Strategic Options	22-03-29	CI
Tyme Technologies to Explore Strategic Options; Shares Rise Pre-Bell	22-03-29	MT
Tyme Technologies Names Douglas Michels Chairman	22-03-25	MT
TYME Technologies, Inc. Announces Changes to its Board of Directors	22-03-25	CI
TYME Technologies, Inc. Announces SM-88 Poster at the American Association for Cancer Research Annual Meeting 2022	22-03-09	CI
Transcript : Tyme Technologies, Inc., Q3 2022 Earnings Call, Feb 11, 2022	22-02-11
Tyme Technologies Narrows Fiscal Q3 Loss	22-02-11	MT

Chart Tyme Technologies, Inc.

Duration

Period

More charts

Company Profile

Tyme Technologies, Inc. is a biotechnology company. The Company is developing cancer metabolism-based therapies (CMBTs ) that are effective across a broad range of solid tumors and hematologic cancers. It is focused on developing its novel compound, SM-88 and its preclinical pipeline of novel CMBT programs. SM-88 is an oral investigational modified proprietary tyrosine derivative that is hypothesized to interrupt the metabolic processes of cancer cells by breaking down the cells? key defenses and leading to cell death through oxidative stress and exposure to the body's natural immune system. Its therapeutic approach is designed to take advantage of a cancer cells innate metabolic weaknesses to cause cancer cell death.

Sector

Biotechnology & Medical Research

More about the company

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
VERTEX PHARMACEUTICALS INCORPORATED	+20.12%	126B
REGENERON PHARMACEUTICALS, INC.	+25.25%	119B
ARGENX SE	+25.56%	27.95B
BIONTECH SE	-19.51%	20.5B
GENMAB A/S	-14.36%	17.12B
BEIGENE, LTD.	-15.63%	16.1B
WUXI APPTEC CO., LTD.	-46.67%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.89%	14.84B
SAREPTA THERAPEUTICS, INC.	+57.74%	14.38B

Bio Therapeutic Drugs